Research Summary

I am a physician scientist focused on the treatment and study of primary liver cancers. I attend in the Gastrointestinal Oncology Group and run a research group in the Quantitive Biosciences Institute. My laboratory applies proteomic methods to identify novel targets and improve the application of existing therapeutics for liver cancers including hepatocellular carcinoma, cholangiocarcinoma and fibrolamellar liver cancer. We have three major areas of investigation:
1. Mapping oncogenic kinase signaling and its response to targeted therapeutics to define biomarkers and combination treatments for clinically relevant agents
2. Characterizing the impact of hepatitis viruses on liver cancer and its response to treatment
3. Developing small molecule strategies to target Hippo pathway dysregulation

Education

Harvard College, Cambridge, MA, BA, 06/2001, Biochemistry
University of Pennsylvania School of Medicine, Philadelphia, PA, PhD, 12/2007, Cancer Biology
University of Pennsylvania School of Medicine, Philadelphia, PA, MD, 05/2009, Medicine
UC San Francisco, Resident, 06/2011, Internal Medicine
UC San Francisco, Clinical Fellow, 07/12, Hematology/Oncology

Honors & Awards

  • 2007
    Nachmias Thimann Prize for Outstanding Graduate Research in Cell and Developmental Biology, University of Pennsylvania
  • 2008
    AACR-GlaxoSmithKline Outstanding Clinical Scholars Award
  • 2008
    Saul Winegrad Award for Outstanding Dissertation in Cell and Molecular Biology, University of Pennsylvania
  • 2008
    AOA Medical Honor Society.
  • 2009
    Kanovsky Prize for the best medical student entering Internal Medicine, University of Pennsylvania.
  • 2015
    American Society for Clinical Oncology Young Investigator Award
  • 2016
    Finalist, Burroughs Wellcome Fund Career Award for Medical Scientists
  • 2017
    Cholangiocarcinoma Foundation Research Fellowship

Selected Publications

  1. Lim HC, Gordan JD Tumor hepatitis B virus RNA identifies a clinically and molecularly distinct subset of hepatocellular carcinoma.  View on PubMed
  2. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.  View on PubMed
  3. Coles GL, Cristea S, Webber JT, Levin RS, Moss SM, He A, Sangodkar J, Hwang YC, Arand J, Drainas AP, Mooney NA, Demeter J, Spradlin JN, Mauch B, Le V, Shue YT, Ko JH, Lee MC, Kong C, Nomura DK, Ohlmeyer M, Swaney DL, Krogan NJ, Jackson PK, Narla G, Gordan JD, Shokat KM, Sage J Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells.  View on PubMed
  4. El Dika I, Mayer RJ, Venook AP, Capanu M, LaQuaglia MP, Kobos R, O'Neill AF, Chou JF, Ly M, Ang C, O'Reilly EM, Gordan JD, Abou-Alfa GK A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma.  View on PubMed
  5. Huppert LA, Gordan JD, Kelley RK Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma.  View on PubMed
  6. Abou-Alfa GK, Mayer R, Venook AP, O'Neill AF, Beg MS, LaQuaglia M, Kingham PT, Kobos R, Basturk O, Brennan C, Yopp A, Harding JJ, Leong S, Crown J, Hoti E, Leonard G, Ly M, Bradley M, Valentino E, Markowitz D, Zukiwski A, Ren K, Gordan JD Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.  View on PubMed
  7. McMahon M, Contreras A, Holm M, Uechi T, Forester CM, Pang X, Jackson C, Calvert ME, Chen B, Quigley DA, Luk JM, Kelley RK, Gordan JD, Gill RM, Blanchard SC, Ruggero D A single H/ACA small nucleolar RNA mediates tumor suppression downstream of oncogenic RAS.  View on PubMed
  8. Wang J, Wang H, Peters M, Ding N, Ribback S, Utpatel K, Cigliano A, Dombrowski F, Xu M, Chen X, Song X, Che L, Evert M, Cossu A, Gordan J, Zeng Y, Chen X, Calvisi DF Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis.  View on PubMed
  9. Kambhampati S, Bauer KE, Bracci PM, Keenan BP, Behr SC, Gordan JD, Kelley RK Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.  View on PubMed
  10. Lou K, Steri V, Ge AY, Hwang YC, Yogodzinski CH, Shkedi AR, Choi ALM, Mitchell DC, Swaney DL, Hann B, Gordan JD, Shokat KM, Gilbert LA KRASG12C inhibition produces a driver-limited state revealing collateral dependencies.  View on PubMed
  11. Wang P, Song X, Utpatel K, Shang R, Yang YM, Xu M, Zhang J, Che L, Gordan J, Cigliano A, Seki E, Evert M, Calvisi DF, Hu X, Chen X MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment.  View on PubMed
  12. Road map for fibrolamellar carcinoma: progress and goals of a diversified approach.  View on PubMed
  13. Xu Y, Poggio M, Jin HY, Shi Z, Forester CM, Wang Y, Stumpf CR, Xue L, Devericks E, So L, Nguyen HG, Griselin A, Gordan JD, Umetsu SE, Reich SH, Worland ST, Asthana S, Barna M, Webster KR, Cunningham JT, Ruggero D Translation control of the immune checkpoint in cancer and its therapeutic targeting.  View on PubMed
  14. Frazier NM, Brand T, Gordan JD, Grandis J, Jura N Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation.  View on PubMed
  15. Song X, Liu X, Wang H, Wang J, Qiao Y, Cigliano A, Utpatel K, Ribback S, Pilo MG, Serra M, Gordan JD, Che L, Zhang S, Cossu A, Porcu A, Pascale RM, Dombrowski F, Hu H, Calvisi DF, Evert M, Chen X Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma.  View on PubMed
  16. Donnella HJ, Webber JT, Levin RS, Camarda R, Momcilovic O, Bayani N, Shah KN, Korkola JE, Shokat KM, Goga A, Gordan JD, Bandyopadhyay S Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer.  View on PubMed
  17. Lim HC, Montesion M, Botton T, Collisson EA, Umetsu SE, Behr SC, Gordan JD, Stephens PJ, Kelley RK Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion.  View on PubMed
  18. Wang J, Dong M, Xu Z, Song X, Zhang S, Qiao Y, Che L, Gordan J, Hu K, Liu Y, Calvisi DF, Chen X Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice.  View on PubMed
  19. Dong M, Liu X, Evert K, Utpatel K, Peters M, Zhang S, Xu Z, Che L, Cigliano A, Ribback S, Dombrowski F, Cossu A, Gordan J, Calvisi DF, Evert M, Liu Y, Chen X Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model.  View on PubMed
  20. Rajaram S, Heinrich LE, Gordan JD, Avva J, Bonness KM, Witkiewicz AK, Malter JS, Atreya CE, Warren RS, Wu LF, Altschuler SJ Sampling strategies to capture single-cell heterogeneity.  View on PubMed

Go to UCSF Profiles, powered by CTSI